AGL:LSE-ANGLE plc (GBX)

COMMON STOCK | Diagnostics & Research | LSE

Last Closing Price

GBX 53.00

Change

0.00 (0.00)%

Market Cap

GBX 0.09B

Volume

0.39M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application. The company was founded in 1994 and is based in Guildford, the United Kingdom. Address: Surrey Research Park, Guildford, United Kingdom, GU2 7AF

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-27 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
IDHC:LSE Integrated Diagnostics Holding..

N/A

GBX0.53B 18.61 0.58
RENX:LSE Renalytix AI plc

N/A

GBX0.32B N/A N/A
NCYT:LSE Novacyt S.A

N/A

GBX0.30B 7.99 5.71
MXCT:LSE MaxCyte, Inc

N/A

GBX0.27B N/A N/A
EKF:LSE EKF Diagnostics Holdings plc

N/A

GBX0.26B 41.30 16.97
HZD:LSE Horizon Discovery Group plc

N/A

GBX0.15B N/A N/A
GDR:LSE genedrive plc

N/A

GBX0.06B N/A N/A
PRM:LSE Proteome Sciences plc

N/A

GBX9.95M 168.50 50.92

ETFs Containing AGL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.47% 33% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.47% 33% F 37% F
Trailing 12 Months  
Capital Gain -35.37% 22% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.37% 22% F 16% F
Trailing 5 Years  
Capital Gain -34.57% 83% B 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.57% 83% B 24% F
Average Annual (5 Year Horizon)  
Capital Gain 1.96% N/A N/A 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.96% N/A N/A 33% F
Risk Return Profile  
Volatility (Standard Deviation) 30.10% N/A N/A 34% F
Risk Adjusted Return 6.51% N/A N/A 30% F
Market Capitalization 0.09B 33% F 45% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.08 86% B 22% F
Price / Cash Flow Ratio -8.72 56% F 80% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -36.45% 29% F 14% F
Return on Invested Capital 22.99% 89% B+ 92% A-
Return on Assets -24.24% 33% F 8% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.21 38% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector